ReviewFrontiers in endocrinology2025
Cardioprotective therapies for ST-elevation myocardial infarction: the emerging role of thyroid hormone: a narrative review.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prehospital 12-Lead ECG Teletransmission in Acute Coronary Syndromes: Diagnostic, Prognostic, and Systems-of-Care Implications.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mortality rates and the incidence of cardiac remodeling and subsequent heart failure remain high, despite ongoing advancements in the management of patients with ST-segment elevation myocardial infarction (STEMI). Most of the adjunctive therapies aiming to further reduce myocardial infarction (MI) size have failed to apply in daily clinical practice. In this context, new promising therapeutic approaches aiming to enhance myocardial salvage have emerged. Recent studies have suggested that thyroid hormone (TH) may have regenerative effects on ischemic myocardium. Immediate treatment with TH appears to trigger repair and the regeneration process in the injured myocardium, especially in patients with large infarct sizes. The aim of this narrative review is to summarize the most recent advances in the use of TH for salvaging ischemic myocardium following STEMI and place it among the most promising cardioprotective therapies. Emphasis is placed on preclinical and clinical data that highlight the favorable effects of TH in enhancing myocardial recovery and improving outcomes after acute myocardial ischemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.